(Q24203876)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22258978%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

meta-analysis

0 references

title

Acetylcholinesterase inhibitors for schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22258978%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22258978%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Jasvinder Singh

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22258978%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Kamalpreet Kour

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22258978%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

language of work or name

English

0 references

publication date

18 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22258978%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22258978%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22258978%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

CD007967

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22258978%20AND%20SRC:MED&resulttype=core&format=json

A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Galantamine for the treatment of cognitive impairments in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Reversal of antiparkinsonian drug toxicity by physostigmine: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Antagonistic Effects of Physostigmine and Methylphenidate in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Parasympathetic suppression of manic symptoms by physostigmine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Cholinergic influences in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Cholinesterase inhibitors for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

How long should treatments be continued?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Quetiapine versus other atypical antipsychotics for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Medical journals and pharmaceutical companies: uneasy bedfellows.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Studies of interference in serial verbal reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Trail Making Test A and B: normative data stratified by age and education

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Cholinergic strategies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

DrugBank: a comprehensive resource for in silico drug discovery and exploration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007967.PUB2

Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia

21 January 2018

1 reference

12 December 2020

[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use]

1 reference

12 December 2020

Rating depressive patients.

1 reference

12 December 2020

Verbal fluency as a function of a measure of verbal intelligence and in relation to different types of cerebral pathology.

1 reference

12 December 2020

Physostigmine and lithium response in the schizophrenias

1 reference

12 December 2020

The use of tacrine for tardive dyskinesia

1 reference

12 December 2020

Identification of a subgroup of tardive dyskinesia patients by pharmacologic probes

1 reference

12 December 2020

Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review

1 reference

12 December 2020

Cognition as an outcome measure in schizophrenia.

1 reference

12 December 2020

1 reference

12 December 2020

[Investigation about an influence of physostigmine on schizophrenic symptoms (author's transl)]

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study

1 reference

12 December 2020

Pharmacologic characterization of tardive dyskinesia

1 reference

12 December 2020

Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion

1 reference

12 December 2020

Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial

1 reference

12 December 2020

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity

1 reference

12 December 2020

Detecting skewness from summary information

1 reference

12 December 2020

Assessing depression in schizophrenia: the Calgary Depression Scale

1 reference

12 December 2020

Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia

1 reference

12 December 2020

Cholinergic challenges in affective illness: behavioral and neuroendocrine correlates

1 reference

12 December 2020

Clinical review of risperidone.

1 reference

12 December 2020

10.1002/14651858.CD007967.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

2402008

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22258978%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

2402008

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22258978%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

2 references

Consolidated OpenCitations Corpus – April 2017

2402008